Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisks (NYSE:NVO) Ozempic for reducing the risk of kidney ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Ozempic being a household name, GLP-1 receptor agonists (GLP-1RAs), a class of medications have garnered significant ...

In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...